Price
No data yet.
Social Signal Score
Analyst Ratings
43 analystsRevenue
$6.26B+51.62%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Rainer Blair
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 59,000
- Beta
- 0.81
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 3.52
Financials
Revenue
$6.26B+51.6%Net Income
$870.00M+122.2%EBITDA
$1.84B+159.0%Free Cash Flow
$1.26B+88.9%EPS (diluted)
$1.23+119.6%Shares Outstanding (diluted)
707.60M+0.9%Operating Expenses
$2.48BCash & Debt
$4.35BReturn of Capital
$1.17BRevenue by Segment (annual)
$24.57BDividend per Share
$0.40Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $24.57B | $3.61B | $5.07 |
| 2024 | $23.88B | $3.90B | $5.33 |
| 2023 | $23.89B | $4.76B | $6.44 |
| 2022 | $26.64B | $7.21B | $9.80 |
| 2021 | $29.45B | $6.43B | $8.77 |
| 2020 | $22.28B | $3.65B | $4.97 |
| 2019 | $17.91B | $2.56B | $3.48 |
| 2018 | $17.05B | $2.65B | $3.78 |
| 2017 | $18.33B | $2.49B | $3.58 |
| 2016 | $16.88B | $2.55B | $3.69 |
| 2015 | $14.43B | $2.60B | $4.81 |
| 2014 | $19.91B | $2.60B | $3.70 |
| 2013 | $19.12B | $2.69B | $3.87 |
| 2012 | $18.26B | $2.30B | $3.45 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from DHR's reported EPS growth of 3.0% a year over 13 years.
- EPS in 5 years
- $5.92
- Implied price
- $266.55
- Return from $214.06
- 4.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $132.52 — -38.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 31 | 38 | 45 | 52 | 59 |
|---|---|---|---|---|---|
| -7.0% | -12.4% | -8.8% | -5.7% | -2.9% | -0.4% |
| -2.0% | -7.7% | -3.9% | -0.6% | 2.3% | 4.9% |
| 3.0% | -3.0% | 1.0% | 4.5% | 7.5% | 10.3% |
| 8.0% | 1.7% | 5.9% | 9.6% | 12.8% | 15.7% |
| 13.0% | 6.4% | 10.8% | 14.6% | 18.0% | 21.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-28.57%Social Signal Score
Mentions (15)
- Newszacks.com·21h ago·Neutral
ELV or DHR: Which Is the Better Value Stock Right Now? Investors interested in stocks from the Medical Services sector have probably already heard of Elevance Health (ELV) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
View source ↗ - Newsprnewswire.com·5d ago·Neutral
Julie Sawyer Montgomery Assumes Role as Danaher President and Chief Executive Officer WASHINGTON, Oct. 1, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or "the Company") announced that, effective today, Julie Sawyer Montgomery has assumed the roles of President and Chief Executive Officer and has joined Danaher's Board of Directors, as previously announced on August 3, 2026. Since joining the Company in 2017, Ms.
View source ↗ - Newszacks.com·5d ago·Positive
DHR's Growth Backed by Strong Biotechnology Unit: Can It Maintain the Pace? Danaher's Biotechnology segment posts 4% sales growth, but tough comparisons and shipment timing could test its momentum.
View source ↗ - Newsetftrends.com·6d ago·Positive
The Top HealthTech Questions Landing on Our Desks Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled this guide to answer a mix of the most frequent and most interesting questions we have received regarding our Healthcare Technology and Innovation Index (HTEC).
View source ↗ - News (RSS)seekingalpha·12d ago·Neutral
Danaher Isn't Anything Special, Even After Absorbing Masimo
View source ↗ - News (Marketaux)seekingalpha.com·12d ago·Neutral
Danaher Isn't Anything Special, Even After Absorbing Masimo (NYSE:DHR) Danaher Isn't Anything Special, Even After Absorbing Masimo (NYSE:DHR)
View source ↗ - Newsprnewswire.com·13d ago·Neutral
Danaher Schedules Third Quarter 2026 Earnings Conference Call WASHINGTON, Sept. 22, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2026 on Wednesday, October 21, 2026 beginning at 8:00 a.m.
View source ↗ - News (RSS)yahoo·17d ago·Neutral
Cardinal Health (NYSE:CAH) Vs Danaher Corporation (NYSE:DHR) – Here’s The One Jim Cramer Said Did Better
View source ↗ - Newsprnewswire.com·20d ago·Neutral
Danaher Announces Quarterly Dividend WASHINGTON, Sept. 15, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on October 30, 2026 to holders of record on September 30, 2026.
View source ↗ - Newszacks.com·20d ago·Positive
ELV or DHR: Which Is the Better Value Stock Right Now? Investors with an interest in Medical Services stocks have likely encountered both Elevance Health (ELV) and Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?
View source ↗ - News (Marketaux)economictimes.indiatimes.com·27d ago·Neutral
DHR Holdings leases 1.8 lakh sq ft in Bengaluru (You can now subscribe to our (You can [+333 characters]
View source ↗ - Newszacks.com·41d ago·Neutral
Danaher Rides on Strength in Biotechnology Segment: Will It Sustain? DHR's Biotechnology segment grows as China demand, bioprocessing and improving discovery markets offset regional headwinds.
View source ↗ - News (RSS)yahoo·43d ago·Positive
Danaher vs. Intuitive Surgical: Is Recovery or Innovation the Better Long-Term Bet?
View source ↗ - News (Marketaux)finance.yahoo.com·43d ago·Positive
Danaher vs. Medtronic: Which Healthcare Recovery Story Has More Upside? Danaher (NYSE:DHR) is [+327 characters]
View source ↗ - Newsseekingalpha.com·52d ago·Positive
Danaher: 2027 Growth Reacceleration Should Drive Upside Danaher is rated a Buy, with revenue growth expected to accelerate in 2027 as respiratory headwinds fade and bioprocessing shipments recover. DHR's valuation is reasonable, trading at a 12% discount to its five-year average P/E, supported by strong recurring revenues and operational excellence. Life Sciences segment shows robust recovery, with 5.5% core growth and margin expansion, driven by improved pharma spending and biotech funding.
View source ↗
Earnings
Wed, Oct 21(in 2 weeks)
Consensus estimate $1.91 per share
Typical surprise +6.2% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Jul 21$1.94 vs $1.85beat
- Tue, Apr 21$2.06 vs $1.94beat
- Wed, Jan 28$2.23 vs $2.16beat
- Tue, Oct 21$1.89 vs $1.72beat
- Tue, Jul 22$1.80 vs $1.64beat
- Tue, Apr 22$1.88 vs $1.63beat
Estimates and results for DHR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DHR officers and directors.
- Bought
- —
- Sold
- $13.0m
0 trades
4 trades
- Blair Rainersold
- Blair Rainersold
- Blair Rainersold
- Spoon Alan Gsold
96 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Kevin Hernhouse · OK01 · disclosed Sep 28, 2026 (26d later)Sell$1,001 - $15,000
- Kevin Hernhouse · OK01 · disclosed Sep 28, 2026 (28d later)Sell$15,001 - $50,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 13, 2026 (27d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 13, 2026 (41d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 13, 2026 (38d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 13, 2026 (40d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 8, 2026 (36d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed May 11, 2026 (13d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Apr 10, 2026 (36d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (12d later)Sell$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Jan 16, 2026 (29d later)Sell$1,001 - $15,000
- Julia Letlowhouse · LA05 · disclosed Jan 13, 2026 (260d later)Buy$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Dec 12, 2025 (29d later)Sell$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Nov 17, 2025 (41d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 14, 2025 (42d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Oct 22, 2025 (27d later)Sell$1,001 - $15,000
- Thomas Keanhouse · NJ07 · disclosed Oct 15, 2025 (42d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2025 (18d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2025 (34d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.